PE20190380A1 - Composiciones para activacion de nrf2 mejorada y sus metodos de uso - Google Patents
Composiciones para activacion de nrf2 mejorada y sus metodos de usoInfo
- Publication number
- PE20190380A1 PE20190380A1 PE2018000340A PE2018000340A PE20190380A1 PE 20190380 A1 PE20190380 A1 PE 20190380A1 PE 2018000340 A PE2018000340 A PE 2018000340A PE 2018000340 A PE2018000340 A PE 2018000340A PE 20190380 A1 PE20190380 A1 PE 20190380A1
- Authority
- PE
- Peru
- Prior art keywords
- extract
- luteolin
- specified
- enhanced
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE: i) EXTRACTO DE ROMERO QUE ESTA ESPECIFICADO AL 5-10% DE CARNOSOL, ii) EXTRACTO DE JENGIBRE QUE ESTA ESPECIFICADO AL 10-20% DE 6-SHOGAOL, iii) LUTEOLINA QUE ESTA ESPECIFICADO AL 95-99% DE LUTEOLINA, iv) EXTRACTO DE CARDO LECHERO, Y v) EXTRACTO DE BACOPA MONNIERI; DONDE LA RELACION ENTRE LOS CINCO COMPONENTES ES DE 10:5:1:30:48 (P/P). DICHA COMPOSICION COMPRENDE DOS O MAS PRODUCTOS FITOQUIMICOS TALES COMO CARNOSOL, ACIDO CARNOSICO, SHOGAOL, GINGEROL, LUTEOLINA Y WITAFERINA A, EN UNA CANTIDAD EFICAZ PARA ACTIVAR LA VIA DE Nrf2 (FACTOR 2 RELACIONADO CON FACTOR NUCLEAR ERITROIDE 2), SIENDO UTIL PARA PREVENIR Y/O TRATAR CONDICIONES DE SALUD ASOCIADAS CON INFLAMACION O ESTRES OXIDATIVO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562214175P | 2015-09-03 | 2015-09-03 | |
US201662355810P | 2016-06-28 | 2016-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190380A1 true PE20190380A1 (es) | 2019-03-08 |
Family
ID=58188643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000340A PE20190380A1 (es) | 2015-09-03 | 2016-09-02 | Composiciones para activacion de nrf2 mejorada y sus metodos de uso |
Country Status (9)
Country | Link |
---|---|
US (1) | US11413269B2 (es) |
JP (1) | JP6901787B2 (es) |
CN (1) | CN108136209A (es) |
CL (1) | CL2018000573A1 (es) |
CO (1) | CO2018003454A2 (es) |
HK (1) | HK1256480A1 (es) |
MX (2) | MX2018002743A (es) |
PE (1) | PE20190380A1 (es) |
WO (1) | WO2017041054A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3481409A4 (en) * | 2016-07-11 | 2020-03-18 | The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) | TREATMENT OF FOLLICULAR TONSILLITIS WITH PLANT EXTRACTS WITH CARNOSIC ACID |
CN110545831A (zh) * | 2017-04-27 | 2019-12-06 | 帝斯曼知识产权资产管理有限公司 | Withania somnifera提取物提供针对空气污染相关疾病的保护的用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
US9265808B2 (en) * | 2004-03-23 | 2016-02-23 | Lifeline Nutraceuticals Corporation | Compositions for alleviating inflammation and oxidative stress in a mammal |
WO2006073042A1 (ja) * | 2005-01-05 | 2006-07-13 | Toagosei Co., Ltd. | Nrf2依存遺伝子の活性化剤 |
CA2648273A1 (en) * | 2006-04-03 | 2007-10-11 | Nestec S.A. | Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same |
EP2265126A4 (en) | 2008-03-10 | 2011-06-29 | Univ Louisville Res Found | METHODS AND COMPOSITIONS FOR CONTROLLED DELIVERY OF PHYTOHEMICAL AGENTS |
JP5608646B2 (ja) | 2008-07-31 | 2014-10-15 | シャクリー コーポレーション | 向上した抗酸化活性を有するマスカダイン組成物 |
JP2011057654A (ja) | 2009-09-14 | 2011-03-24 | Iwate Univ | メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法 |
WO2011075843A1 (en) | 2009-12-24 | 2011-06-30 | The Royal Institution For The Avancement Of Learning/Mcgill University | Compositions and methods for preventing and treating diseases and environmentally induced health disorders |
KR101254847B1 (ko) * | 2010-05-27 | 2013-04-15 | 한림대학교 산학협력단 | 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물 |
WO2012142511A2 (en) | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
WO2013108056A1 (es) * | 2012-01-16 | 2013-07-25 | Velez-Rivera Hector De Jesus | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares |
JP2013209351A (ja) * | 2012-03-30 | 2013-10-10 | Sunstar Inc | 抗酸化機能亢進剤 |
US20140287071A1 (en) * | 2013-01-17 | 2014-09-25 | Lifevantage Corporation | Veterinary supplements |
WO2014151891A1 (en) | 2013-03-14 | 2014-09-25 | Walley Darlene | Topical products |
US10596115B2 (en) * | 2013-07-17 | 2020-03-24 | Council Of Scientific & Industrial Research | Pharmaceutical composition for the treatment of diminution of bone tissue |
WO2016037971A1 (en) | 2014-09-08 | 2016-03-17 | Bios Line S.P.A. | Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary |
-
2016
- 2016-09-02 CN CN201680050947.0A patent/CN108136209A/zh active Pending
- 2016-09-02 PE PE2018000340A patent/PE20190380A1/es unknown
- 2016-09-02 MX MX2018002743A patent/MX2018002743A/es unknown
- 2016-09-02 WO PCT/US2016/050292 patent/WO2017041054A1/en active Application Filing
- 2016-09-02 JP JP2018531303A patent/JP6901787B2/ja active Active
- 2016-09-02 US US15/757,270 patent/US11413269B2/en active Active
-
2018
- 2018-03-02 MX MX2022009446A patent/MX2022009446A/es unknown
- 2018-03-02 CL CL2018000573A patent/CL2018000573A1/es unknown
- 2018-03-27 CO CONC2018/0003454A patent/CO2018003454A2/es unknown
- 2018-12-04 HK HK18115518.1A patent/HK1256480A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017041054A1 (en) | 2017-03-09 |
US20180250264A1 (en) | 2018-09-06 |
CL2018000573A1 (es) | 2019-01-11 |
CN108136209A (zh) | 2018-06-08 |
HK1256480A1 (zh) | 2019-09-27 |
CO2018003454A2 (es) | 2018-08-31 |
MX2022009446A (es) | 2022-09-05 |
MX2018002743A (es) | 2018-06-06 |
US11413269B2 (en) | 2022-08-16 |
JP2018529763A (ja) | 2018-10-11 |
JP6901787B2 (ja) | 2021-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019008087A2 (es) | Método para modular la actividad de inflamasoma e inflamación en el pulmón | |
AR102372A1 (es) | Composición que comprende una mezcla de extractos vegetales o una mezcla de moléculas contenidas en dichos vegetales, y su utilización para actuar sobre el metabolismo glucídico y/o lipídico | |
NI201600164A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
CL2018001006A1 (es) | Composiciones farmacéuticas para terapia combinada (sol. divisional de n° 201701983) | |
CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
CL2015003346A1 (es) | Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas | |
CR20160093A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica | |
UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
CL2015002083A1 (es) | Composiciones herbicidas sinergicas | |
BR112016018085A8 (pt) | composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
CO2018005971A2 (es) | Composición de regulador de crecimiento vegetal que tiene efecto sinérgico | |
CL2016000038A1 (es) | Piraxolo-piridinaminas sustituidas | |
CO2021001172A2 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
AR097143A1 (es) | Composición alimenticia mineral para lamer para rumiantes y método para prepararla | |
PE20190380A1 (es) | Composiciones para activacion de nrf2 mejorada y sus metodos de uso | |
CU20160139A7 (es) | Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos |